Dr Hamid on the Rationale For Investigating Fianlimab Plus Cemiplimab in Melanoma

Commentary
Video

In Partnership With:

Omid Hamid, MD, director, Melanoma Program, The Angeles Clinic and Research Institute, Cedars-Sinai, discusses the rationale for a phase 1 trial of fianlimab plus cemiplimab in patients with advanced melanoma who have received prior adjuvant PD-1 inhibitors.

Omid Hamid, MD, director, Melanoma Program, The Angeles Clinic and Research Institute, Cedars-Sinai, discusses the rationale for a phase 1 trial of fianlimab (formerly REGN 3767) plus cemiplimab-rwlc (Libtayo) in patients with advanced melanoma who have received prior adjuvant PD-1 inhibitors.

Fianlimab is a LAG3 inhibitor, and cemiplimab is a PD-1 inhibitor. The combination of PD-1 inhibition and LAG3 inhibition has been shown to improve response rates and progression-free survival in patients with advanced melanoma, Hamid says. Initial data from this phase 1 trial were presented at the 2022 ESMO Congress. These data demonstrated a 64% overall response rate (ORR) in patients with advanced melanoma who were naive to PD-1 inhibition.

Updated findings from this trial, which were presented at the 2023 ASCO Annual Meeting, include follow-up data from the PD-1 inhibitor–naive population. The presentation also included novel data in a population of patients with pretreated melanoma, including those with prior exposure to adjuvant PD-1 inhibitors.

At a median follow-up of 11.5 months (interquartile range, 8.9-13.9), patients in the confirmatory PD-1 inhibitor–naive cohort (n = 40) achieved an ORR of 63% (95% CI, 46%-77%). The median duration of response (DOR) in this cohort was not reached (NR; 95% CI, not evaluable [NE]-NE), and the disease control rate (DCR) was 80% (95% CI, 64%-91%). Best overall responses of complete response (CR), partial response (PR), stable disease (SD), partial disease (PD), and NE were observed in 13%, 50%, 18%, 15%, and 5% of patients in this cohort, respectively.

At a median follow-up of 9.7 months (95% CI, 4.8-14.1), patients in the PD-1 inhibitor–experienced cohort (n = 18) achieved an ORR of 56% (95% CI, 31%-79%). The median DOR in this cohort was NR (95% CI, 6 months-NE), and the DCR was 67% (95% CI, 41%-87%). Best overall responses of CR, PR, SD, PD, and NE were observed in 6%, 50%, 11%, 28%, and 6% of patients in this cohort, respectively.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD